GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » Days Inventory

Bioverativ (Bioverativ) Days Inventory : 46.14 (As of Dec. 2017)


View and export this data going back to 2017. Start your Free Trial

What is Bioverativ Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Bioverativ's Average Total Inventories for the three months ended in Dec. 2017 was $36 Mil. Bioverativ's Cost of Goods Sold for the three months ended in Dec. 2017 was $70 Mil. Hence, Bioverativ's Days Inventory for the three months ended in Dec. 2017 was 46.14.

The historical rank and industry rank for Bioverativ's Days Inventory or its related term are showing as below:

BIVV's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 192.335
* Ranked among companies with meaningful Days Inventory only.

Bioverativ's Days Inventory declined from Dec. 2016 (352.77) to Dec. 2017 (46.14).

Inventory Turnover measures how fast the company turns over its inventory within a year. Bioverativ's Inventory Turnover for the three months ended in Dec. 2017 was 1.98.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Bioverativ's Inventory-to-Revenue for the three months ended in Dec. 2017 was 0.11.


Bioverativ Days Inventory Historical Data

The historical data trend for Bioverativ's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ Days Inventory Chart

Bioverativ Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Days Inventory
- 1,886.01 1,488.29 425.07 223.62

Bioverativ Quarterly Data
Dec13 Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 352.77 283.55 80.14 56.07 46.14

Competitive Comparison of Bioverativ's Days Inventory

For the Biotechnology subindustry, Bioverativ's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioverativ's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioverativ's Days Inventory distribution charts can be found below:

* The bar in red indicates where Bioverativ's Days Inventory falls into.



Bioverativ Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Bioverativ's Days Inventory for the fiscal year that ended in Dec. 2017 is calculated as

Days Inventory (A: Dec. 2017 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2016 ) + Total Inventories (A: Dec. 2017 )) / count ) / Cost of Goods Sold (A: Dec. 2017 )*Days in Period
=( (302 + 40.6) / 2 ) / 279.6*365
=171.3 / 279.6*365
=223.62

Bioverativ's Days Inventory for the quarter that ended in Dec. 2017 is calculated as:

Days Inventory (Q: Dec. 2017 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2017 ) + Total Inventories (Q: Dec. 2017 )) / count ) / Cost of Goods Sold (Q: Dec. 2017 )*Days in Period
=( (30.5 + 40.6) / 2 ) / 70.3*365 / 4
=35.55 / 70.3*365 / 4
=46.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioverativ  (NAS:BIVV) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Bioverativ's Inventory Turnover for the three months ended in Dec. 2017 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Bioverativ's Inventory to Revenue for the three months ended in Dec. 2017 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Bioverativ Days Inventory Related Terms

Thank you for viewing the detailed overview of Bioverativ's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioverativ (Bioverativ) Business Description

Traded in Other Exchanges
N/A
Address
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox director, officer: Chief Executive Officer C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene officer: EVP, CFO and Treasurer 51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia director C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall officer: Chief Accounting Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio officer: EVP, Chief Global Therapeutics 225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r. officer: EVP, R & D C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona officer: EVP, HR & Corp Commun. Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick officer: EVP, Business Development BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu 06-29-2017

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood 05-24-2017

5 Companies Hit 52-Week Highs

By yifan900 yifan900 05-29-2018